| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Division of Neurology, Duke University Medical Center, Durham, NC.
Address correspondence and reprint requests to Dr. Emma Ciafaloni, Duke University Medical Center, Division of Neurology, DUMC 3403, Durham, NC 27710; e-mail: ciafa001{at}mc.duke.edu
In an open-label study, 12 patients with refractory MG or who were taking only corticosteroids and required additional immunosuppression received mycophenolate mofetil 1 g twice daily for 6 months. A reduction of three points in a quantified MG score and two points in a manual muscle test or a reduction of 50% in corticosteroid dose defined efficacy. Eight patients improved, beginning after 2 weeks to 2 months. No major side effects were observed.
This article has been cited by other articles:
|
|
 |
|
  M. Benatar and L. P. Rowland The muddle of mycophenolate mofetil in myasthenia Neurology, August 5, 2008; 71(6): 390 - 391. [Full Text] [PDF]
|
|
|
|
|
|
The Muscle Study Group A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis Neurology, August 5, 2008; 71(6): 394 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Sanders, I. K. Hart, R. Mantegazza, S. S. Shukla, Z. A. Siddiqi, M.H.V. De Baets, A. Melms, M. W. Nicolle, N. Solomons, and D. P. Richman An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis Neurology, August 5, 2008; 71(6): 400 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Piepers, R. Van den Berg-Vos, W-L. Van der Pol, H. Franssen, J. Wokke, and L. Van den Berg Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial Brain, August 1, 2007; 130(8): 2004 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. D Cahoon Jr and D. R Kockler Mycophenolate Mofetil Treatment of Myasthenia Gravis Ann. Pharmacother., February 1, 2006; 40(2): 295 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Bedlack, D. L. Simel, H. Bosworth, G. Samsa, B. Tucker-Lipscomb, and D. B. Sanders Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity Neurology, June 14, 2005; 64(11): 1968 - 1970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Ciafaloni Mycophenolate mofetil and myasthenia gravis Lupus, March 1, 2005; 14(3_suppl): s46 - s49. [Abstract] [PDF]
|
|
|
|
 |
|
 V. Majithia and V. Harisdangkul Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy Rheumatology, March 1, 2005; 44(3): 386 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ciafaloni Mycophenolate mofetil and myasthenia gravis Lupus, January 1, 2005; 14(1_suppl): s46 - s49. [Abstract] [PDF]
|
|
|
|
 |
|
 M. J. Kothari Myasthenia Gravis J Am Osteopath Assoc, September 1, 2004; 104(9): 377 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Richman and M. A. Agius Treatment of autoimmune myasthenia gravis Neurology, December 23, 2003; 61(12): 1652 - 1661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.N. Meriggioli, E. Ciafaloni, K.A. Al-Hayk, J. Rowin, B. Tucker-Lipscomb, J.M. Massey, and D.B. Sanders Mycophenolate mofetil for myasthenia gravis: An analysis of efficacy, safety, and tolerability Neurology, November 25, 2003; 61(10): 1438 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Evoli, C. Minisci, C. Di Schino, F. Marsili, C. Punzi, A. P. Batocchi, P. A. Tonali, G. B. Doglietto, P. Granone, L. Trodella, et al. Thymoma in patients with MG: Characteristics and long-term outcome Neurology, December 24, 2002; 59(12): 1844 - 1850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Pruitt II and T. R. Swift Therapies for Disorders of the Neuromuscular Junction Arch Neurol, May 1, 2002; 59(5): 739 - 742. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
